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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a life-threatening neurodegenerative disease involving upper and lower
motor neurons loss. Clinical features are highly variable among patients and there are currently few known disease-
modifying factors underlying this heterogeneity. Serotonin is involved in a range of functions altered in ALS, including
motor neuron excitability and energy metabolism. However, whether serotoninergic activity represents a disease modifier
of ALS natural history remains unknown.
Methodology: Platelet and plasma unconjugated concentrations of serotonin and plasma 5-HIAA, the major serotonin
metabolite, levels were measured using HPLC with coulometric detection in a cohort of 85 patients with ALS all followed-up
until death and compared to a control group of 29 subjects.
Principal Findings: Platelet serotonin levels were significantly decreased in ALS patients. Platelet serotonin levels did not
correlate with disease duration but were positively correlated with survival of the patients. Univariate Cox model analysis
showed a 57% decreased risk of death for patients with platelet serotonin levels in the normal range relative to patients
with abnormally low platelet serotonin (p=0.0195). This protective effect remained significant after adjustment with age,
gender or site of onset in multivariate analysis. Plasma unconjugated serotonin and 5-HIAA levels were unchanged in ALS
patients compared to controls and did not correlate with clinical parameters.
Conclusions/Significance: The positive correlation between platelet serotonin levels and survival strongly suggests that
serotonin influences the course of ALS disease.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disorder affecting both lower motor neurons (LMN) and upper
motor neurons (UMN), and leads to death within 2 to 5 years of
onset. Clinical features and progression are highly heterogeneous
among patients (for review see [1]). There are currently few
identified disease-modifying factors accounting for this heteroge-
neity. Among these, energy metabolism abnormalities have been
shown in ALS patients [2,3,4,5] and their potential contribution to
the course of the disease has been stressed [6], but little is known
about the factors triggering these abnormalities.
The neurotransmitter serotonin is involved in a range of
functions altered in ALS, including motor neuron excitability and
energy metabolism (reviewed in [7,8,9]). Early studies on very
limited numbers of patients suggested that the levels of serotonin
and its metabolite are decreased in brain tissues of ALS patient’s
post-mortem [10,11,12]. Moreover, recent imaging studies have
shown decreased binding of serotonin 1A (5-HT1A) ligands in
ALS raphe and cortex [13]. However, definite evidence that
serotonin itself is modified in ALS is lacking and whether
serotonergic activity is a disease modifier of ALS natural history
remains unknown. Since serotonergic neurons and platelets
express similar serotonin related enzymes and receptor, alterations
in central serotonin are likely to be reflected in platelet serotonin
levels [14,15,16]. In this study we aimed to study the relationships
between circulating serotonin and survival in a cohort of ALS
patients.
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Decreased platelet serotonin levels in ALS patients
The demographic data of ALS patients (Table 1) are in close
accordance with previous reports thus showing that the patients
included in the present study are representative of the ALS
population. Age and sex ratio of ALS and control groups did not
differ (Table 1). Levels of platelet serotonin were significantly lower
in ALS patients (median [range] ng/mL: 78.4 [5.2–232.1]) as
compared to controls (median [range] ng/mL: 110.6 [41.4–239.6],
p=0.0003) with a global 30% decrease in ALS patients (Table 2).
Normal values of the laboratory range from 60 to 200 ng/mL
(N=69 patients) [17,18]. Compared to normal value of the
laboratory, 31% of ALS patients displayed values below the normal
range, as compared to 6% of controls. Plasma unconjugated
serotonin and 5-HIAA remained unchanged. The decreased
platelet serotonin levels were found in patients with either bulbar
or spinal onset (Table 3). Levels of plasma unconjugated serotonin
were decreased in bulbar, but not in spinal onset patients compared
to controls (Table 3). 5-HIAA plasma levels were similar in controls
and in patients whatever was the site of onset, and the molar ratio
between 5-HIAA and platelet serotonin (an index of MAO-A
activity) was significantly increased in ALS patients compared to
matched controls (Table 2), and this was mostly due to bulbar onset
patients. This difference between bulbar and spinal onset patients
was not due to a difference in nutritional status between these two
groups since BMI did not differ significantly (bulbar onset patients:
24.663.5; spinal onset patients: 24.763.4; p.0.05).
Decreased platelet serotonin is predictive of worsened
survival of ALS patients
There was a significant decrease of platelet serotonin with
increasing age at blood sampling in ALS patients (R squared =
0.053, p=0.0365) but not in controls (R squared =0.004825,
p=0.72). In the ALS patients group, there was no relationship of
platelet serotonin with the length of disease prior to sampling (R
squared =0.016324 p=0.2527). Platelet serotonin levels showed
no correlation with either site of onset, sex, Norris score slopes,
initial BMI or rate of BMI loss. Neither plasma serotonin nor
5-HIAA levels correlated with any of the clinical parameters.
Overall median survival, calculated from time of sampling to
death, was 34 months [range: 1-149]. Univariate Cox model
analysisof survivalshowed a significantincreaseof risk ofdeathwith
increasing age(Coxmodel,RR[95%CI] (peryear) =1.028[1.004–
1.055], p=0.0210) and significant decrease of the risk of death with
increasing platelet serotonin levels (Cox model, RR [95%CI] (per
ng/mL) =0.994 [0.989–0.999], p=0.0195). We broke down
patient population in 3 groups according to platelet serotonin
levels. Values were considered as in a high normal range when
superior to 100 ng/mL (i.e. approximately the mean of controls), in
an abnormal low range when inferior to 50 ng/mL, and in a
borderline range between 50 and 100 ng/mL. This analysis showed
a good linearity of the platelet serotonin levels on survival (Figure 1).
Patients in the high normal values range showed a 57% decreased
risk of death relative to the abnormal low values range and 35%
relativetotheborderline one(p=0.023 bythelog-ranktest,Figure).
Platelet serotonin remained a significant independent predictor of
survival followingadjustment onknown prognosticvariables such as
age, or site of onset or gender (RR [95%CI] (per ng/mL) =0.995
[0.990–0.999], p=0.046; RR [95%CI] (per ng/mL) =0.984
[0.989–0.999], p=0.020 and RR [95%CI] (per ng/mL) =0.995
[0.989–0.999], p=0.026 respectively).
Discussion
Our study provides two important results, (i) platelet serotonin
levels are significantly decreased in ALS patients relative to
matched controls, and (ii) platelet serotonin level is a significant
predictor of survival independent of age.
We first show that platelet serotonin levels are globally
decreased in ALS patients, with about one third of ALS patients
displaying levels of platelet serotonin below the normal range.
Platelets are usually considered as an easily accessible model of
central serotonergic neurons due to similarities in enzymatic and
receptor equipments [14,16]. Thus, the decreased platelet
serotonin levels could mirror what has been reported in ALS
Table 1. Demographic parameters in ALS and control groups.
Item (+/2SD) ALS patients Controls
N8 5 2 9
Mean age at blood sampling (years) 61.65610.5 61.0614.4
Sex ratio (M/F) 1.24 1.18
Bulbar site of onset (bulbar/spinal) 34% (29/56)
Age at onset (years) 60.369.9
Age at death (years) 64.2069.8
Survival (months) 45.9640.7
BMI (kg/m
2) 24.763.5
doi:10.1371/journal.pone.0013346.t001
Table 2. Serotonin levels in ALS and control groups.
Variables
(mean ± SD; n) ALS patients Controls P value
Platelet serotonin
(ng/mL)
83.4650.3; 82 124.3647.7; 29 0.0003
Plasma unconjugated
serotonin (ng/mL)
1.3561.78; 82 1.4161.20; 29 NS
Plasma 5-HIAA
(ng/mL)
7.3564.07; 72 7.7162.38; 29 NS
5-HIAA/platelet serotonin
molar ratio
0.1460.20; 70 0.0760.04; 29 0.012
Groups were compared using Mann-Whitney test and the p-value is shown.
doi:10.1371/journal.pone.0013346.t002
Table 3. Serotonin levels in ALS patients as a function
of site of onset.
Item (+/2SD; n)
ALS patients
(Bulbar onset)
ALS patients
(Spinal onset) Controls
Platelet serotonin
(ng/mL)
76.9647.5; 28** 86.8651.7; 54** 124.3647.7; 29
Plasma unconjugated
serotonin (ng/mL)
0.8861.08; 26* 1.5662.00; 56 1.4161.20; 29
Plasma 5-HIAA
(ng/mL)
8.0063.31; 23 7.0464.37; 49 7.7162.38; 29
5-HIAA/platelet
serotonin molar ratio
0.2160.30; 22* 0.1260.13; 49 0.0760.04; 29
Groups were compared using Kruskal Wallis test. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0013346.t003
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metabolite as well as a decreased binding of 5-HT1A ligand in the
brain [9,10,11,12,13]. Patients with bulbar onset displayed a more
profound impairment of the serotonergic system since plasma
unconjugated serotonin levels were also decreased in this
population, in contrast with patients with spinal onset. This is in
line with a more pronounced loss of cortical 5-HT1A binding
observed in bulbar onset patients [13].
The causes of serotonin decrease remain elusive. Number of
neurologic and psychiatric conditions, including Alzheimer’s
disease [19], are associated with decreases of the serotonergic
system either centrally or in platelets or both. A similar decrease in
serotonin has been described in frontotemporal dementia [20],
which is now thought to form a continuum with ALS [21]. Platelet
serotonin decrease was also found in depression, although to a
lesser extent [18,22,23] and in violent suicide attempters [24].
Consistent with a pathogenic role of serotonin decrease in ALS,
number of studies showed that depression in ALS worsens disease
severity [25,26,27]. In all, our current study supports the existence
of a marked impairment of the serotonergic system in a significant
proportion of ALS patients. It should be pointed out that
decreased levels of platelet serotonin have been reported in many
different pathological or debilitating conditions, notably in
psychiatric and neurologic diseases, and thus platelet serotonin
levels in ALS, as observed decreased here, should not be
considered as a specific biomarker of ALS. Another limitation of
our study is that serotonin levels were assayed in blood, at one
single time point. Future studies should be longitudinal and
measure brain-derived serotonin in the CSF.
The second major result of this study is that platelet serotonin
levels correlated positively with survival, as calculated from time of
sampling to death. Numbers of studies have shown that serotonin
levels drop with age [28]. Since age is a known modifier of ALS
survival, [29] it was critical to determine whether the observed
correlation was related to age and not to the disease process. In our
study, platelet serotonin did not correlate with age in controls. This
is likelytobe duetotherelativelynarrowage rangeof patients,since
the most important variations of serotonin with age occur in the first
two decades of life [30]. In the ALS population, after adjustment
with age in a multivariate Cox model, platelet serotonin remained a
significant predictor of survival, thus showing that the correlation
between platelet serotonin and survival unlikely results from an
effect of age on platelet serotonin levels. Another potential
confounding factor in studies with serotonin is drug interactions.
The observed correlations were not due to such drug interactions
since patients taking serotonin reuptake inhibitors, antidepressants
or any other serotonin related medications were excluded from the
study. It should be noted that in this study, serotonin was measured
at one single time point, when disease had already been diagnosed.
Thus, serotonin decrease might be either preexisting disease onset
and be associated with an intrinsic variation in serotonin
metabolism, or be the consequence of the disease process itself.
The observed positive correlation might, in this latter case be due to
an upstream mechanism able to modify both ALS course and
serotonin levels. In this case, serotonin decrease would be a
surrogate marker of a crucial, still unknown, pathogenic event. In
the current absence of longitudinal studies or of genetic studies on
serotonin-related genes, it remains impossible to discriminate
between these two hypothesis.
Previous research in animal models of ALS however supports
that serotonin might directly modulate onset and survival in ALS.
The administration of serotonin precursor 5-hydroxytryptophan
delayed onset and mortality in a transgenic mice ALS model [31].
The mechanisms underlying the potential protection by serotonin
in ALS clearly deserve further investigation. It seems unlikely that
the potential positive effect of serotonin on survival is related to the
excitatory action on motor neurons [7,8,32] since increased
serotonin potentially exacerbates a glutamate-evoked excitotoxic-
ity [9]. A more attractive hypothesis is a relationship between
serotonin and energy metabolism. Serotonin modulates energy
Figure 1. Correlation between platelet serotonin levels and survival in patients with amyotrophic lateral sclerosis (ALS). Kaplan-
Meyer survival curves of patients with ALS stratified according to their platelet serotonin levels. Survival was calculated as the time period between
blood sampling and death. The black line represents patients with ALS having abnormal serotonin values (serotonin ,50 ng/mL, n=22 patients);
light grey line represents patients with high normal values (serotonin .100 ng/mL i.e. median of control group, n=25 patients), and light black line
patients with borderline values (50–100 ng/mL, n=35 patients). Group comparison shows a statistically significant difference (p=0.024 by the log-
rank).
doi:10.1371/journal.pone.0013346.g001
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mechanisms [33]. A large number of ALS patients as well as
transgenic ALS mice show increased energy expenditure
[3,4,5,34], a phenotype which appears analogous to the effects
of a chronic depletion in brain-derived serotonin [35]. Future
studies should focus on the potential relationships between
serotonin and energy metabolism in ALS.
Whether serotonin directly modulates disease course or
constitute a surrogate marker of another crucial pathogenic event,
our results show that platelet serotonin correlates with survival in
ALS. To our knowledge, few biological factors have been
demonstrated to be associated with survival in ALS. Among them
are the increase of LDL/HDL ratio [6], of plasma ApoE [36], the
polymorphisms in the kifap3 gene [37] or more recently CSF glial
markers [38]. In the current state of knowledge, our results do not
indicate that serotonin replacement therapy could be useful for
patients, but rather that investigations focused on the serotonergic
system in ALS are warranted.
Materials and Methods
Ethics statement
Patients were informed of the aim of this non-interventional
research and gave their written informed consent. The institu-
tional review board of Salpe ˆtrie `re hospital approved the research.
Control patients gave their written informed consent for
participating in this study.
Patients
Blood samples were collected from 90 patients followed at the
Pitie ´ Salpetrie `re hospital (Paris, France) between 1994 and 1995.
All patients met the El Escorial World Federation of Neurology
criteria for the diagnosis of definite or probable ALS at the time of
blood sampling. Patients underwent blood sampling after diagnosis
and before riluzole treatment. Control samples were collected
from 11 healthy volunteers and 18 patients hospitalized for
orthopaedic surgery. There was no difference in any of the
measured parameters between healthy volunteers and orthopaedic
patients and they were thus considered as a single control group.
Controls were age and sex matched and medical examinations
excluded neurodegenerative, inflammatory, psychiatric (in partic-
ular depression and food intake disorders, such as anorexia) or
neoplasic disorders of the nervous system. All blood samples were
taken as a part of routine laboratory evaluations and were collected
after a 12 h fasting period, with care taken to avoid possible
medications and possible diets and dietary problems known to
interfere with serotonin levels. For controls undergoing orthopaedic
surgery, blood samples were taken before any surgery to avoid for
the potential biasesdueto surgery orimmobilization. Allindividuals
included in the study, either patients or controls, did not used
serotonin reuptake inhibitors or any medication with known
interaction with serotonin (e.g. antidepressants). Death was docu-
mented by death certificate or written letter from relatives or
physicians. Documented time of death was obtained for all patients
but 5 who were lost to follow-up and had no information after
sampling visit. Database was closed at 1st October 2009 and these 5
patients were excluded from the study. Survival was defined as time
from blood sampling to death. Disease duration was calculated as
thetime intervalbetweenfirstsymptomsand bloodsampling.These
values were calculated in months. Body mass index (BMI) was
calculated at each visit and BMI loss was calculated using a linear
regression model. Bulbar and Limbs Norris scale scores were
assessed at sampling visit and at each subsequent visit.
Biochemical procedures
Circulating serotonin was measured in serum; while plasma
unconjugated serotonin and 5-HIAA levels were measured in
plasma. Platelet serotonin, which corresponds to about 98% of
total circulating serotonin, was calculated as the difference
between circulating and plasma unconjugated serotonin concen-
trations. The molar ratio between platelet serotonin and 5-HIAA
levels was calculated and used as an indirect index of MAO-A
activity. All the patients and the control subjects fasted overnight.
Samples of blood were drawn from the anterocubital vein between
7AM and 10AM. Five millilitres of blood were collected into
Vacutainer tubes with no additive for circulating 5-HT, with
citrate for plasma unconjugated serotonin and with dry heparin for
plasma 5-HIAA levels. Serum and plasma were separated by
centrifugation at 3000 g and stored at –80uC until further analysis
without additional thawing. The results were unrelated to storing
time. The three parameters were determined within 6 months
after blood sampling by high-performance liquid chromatography
with coulometric detection according to three different analytical
procedures previously described [39,40]. The minimum quantifi-
able level of serotonin was 0.05 ng/mL in plasma and serum. The
day-to-day variations were 2.0%, 3.0% and 2.7% for 25, 100 and
300 ng/mL respectively (n=8) for serum serotonin and 8.6%,
7.0% and 5.6% for 0.5, 5 and 10 ng/mL plasma serotonin levels
(n=8). For plasma 5-HIAA assays, the minimum quantifiable level
was 1 ng/mL with the day-to-day coefficient of variation of 14%
and 11.2% for 6 and 21 ng/mL (n=10) respectively.
Statistical analysis
Data are expressed as mean 6 SD and/or median [range].
Based on normal values of the laboratory (mean [95% CI]: 92.7
[83.4–101.9] ng/ml) [17,18] we calculated that we could detect at
least a 26% change in patients (n=85) as compared to controls
(n=29) with 81% power and p-alpha (2-tailed)=0.05, by the T
test. For group comparisons (ALS vs. controls), we performed non-
parametric Mann-Whitney tests. For comparisons of three groups
(control vs. ALS patients with spinal onset or bulbar onset), we
used Kruskal Wallis tests. Correlations were performed using the
nonparametric Spearman’s rank correlation test.
Univariate and multivariate Cox model analysis were per-
formed to assess the effects of candidate variables on survival. To
assess the linearity of platelet serotonin levels on survival, patient
population was broken-down in 3 groups according to (i) high
normal values (cut-off . median of control group=100 ng/mL
i.e. circa 550 nM, 25 patients), (ii) abnormal low values (cut-off
below the normal range ,50 ng/mL i.e. circa 280 nM, 22
patients) and (iii) borderline values (50–100 ng/mL, 35 patients).
Survival curves for the three groups were compared by the Mantel
Cox (log rank) statistic. Data were analysed using JMP software
(version 8.0; SAS Institute Inc., Cary, NC), and statistical
threshold for statistical significance set at p (a 2-tailed) ,0.05.
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